Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

Huilin Tang, Wei Cui, Dandan Li, Tiansheng Wang, Jingjing Zhang, Suodi Zhai, Yiqing Song

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Given inconsistent trial results of sodium-glucose cotransporter 2 (SGLT2) inhibitors in addition to insulin therapy for treating type 2 diabetes mellitus (T2DM), a meta-analysis was performed to evaluate the efficacy and safety of this combination for T2DM by searching available randomized trials from PubMed, Embase, CENTRAL and ClinicalTrials.gov. Our meta-analysis included seven eligible placebo-controlled trials involving 4235 patients. Compared with placebo, SGLT2 inhibitor treatment was significantly associated with a mean reduction in HbA1c of −0.56%, fasting plasma glucose of −0.95 mmol/L, body weight of −2.63 kg and insulin dose of −8.79 IU, but an increased risk of drug-related adverse events by 36%, urinary tract infections by 29% and genital infections by 357%. No significant increase was observed in risk of overall adverse events [risk ratio (RR), 1.00], serious adverse events (RR, 0.90), adverse events leading to discontinuation (RR, 1.16), hypoglycaemia events (RR, 1.07) and severe hypoglycaemia events (RR, 1.24). No diabetic ketoacidosis events were reported. Further studies are needed to establish optimal combination type and dose.

Original languageEnglish (US)
Pages (from-to)142-147
Number of pages6
JournalDiabetes, Obesity and Metabolism
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Sodium-Glucose Transporter 2
Symporters
Type 2 Diabetes Mellitus
Meta-Analysis
Randomized Controlled Trials
Odds Ratio
Insulin
Sodium-Glucose Transport Proteins
Hypoglycemia
Placebos
Therapeutics
Diabetic Ketoacidosis
Drug-Related Side Effects and Adverse Reactions
PubMed
Urinary Tract Infections
Fasting
Body Weight
Safety
Glucose
Infection

Keywords

  • insulin therapy
  • meta-analysis
  • SGLT2 inhibitor
  • type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus : A meta-analysis of randomized controlled trials. / Tang, Huilin; Cui, Wei; Li, Dandan; Wang, Tiansheng; Zhang, Jingjing; Zhai, Suodi; Song, Yiqing.

In: Diabetes, Obesity and Metabolism, Vol. 19, No. 1, 01.01.2017, p. 142-147.

Research output: Contribution to journalArticle

@article{e7fdcb4030eb448c8a808e8439d6d167,
title = "Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials",
abstract = "Given inconsistent trial results of sodium-glucose cotransporter 2 (SGLT2) inhibitors in addition to insulin therapy for treating type 2 diabetes mellitus (T2DM), a meta-analysis was performed to evaluate the efficacy and safety of this combination for T2DM by searching available randomized trials from PubMed, Embase, CENTRAL and ClinicalTrials.gov. Our meta-analysis included seven eligible placebo-controlled trials involving 4235 patients. Compared with placebo, SGLT2 inhibitor treatment was significantly associated with a mean reduction in HbA1c of −0.56{\%}, fasting plasma glucose of −0.95 mmol/L, body weight of −2.63 kg and insulin dose of −8.79 IU, but an increased risk of drug-related adverse events by 36{\%}, urinary tract infections by 29{\%} and genital infections by 357{\%}. No significant increase was observed in risk of overall adverse events [risk ratio (RR), 1.00], serious adverse events (RR, 0.90), adverse events leading to discontinuation (RR, 1.16), hypoglycaemia events (RR, 1.07) and severe hypoglycaemia events (RR, 1.24). No diabetic ketoacidosis events were reported. Further studies are needed to establish optimal combination type and dose.",
keywords = "insulin therapy, meta-analysis, SGLT2 inhibitor, type 2 diabetes",
author = "Huilin Tang and Wei Cui and Dandan Li and Tiansheng Wang and Jingjing Zhang and Suodi Zhai and Yiqing Song",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/dom.12785",
language = "English (US)",
volume = "19",
pages = "142--147",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus

T2 - A meta-analysis of randomized controlled trials

AU - Tang, Huilin

AU - Cui, Wei

AU - Li, Dandan

AU - Wang, Tiansheng

AU - Zhang, Jingjing

AU - Zhai, Suodi

AU - Song, Yiqing

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Given inconsistent trial results of sodium-glucose cotransporter 2 (SGLT2) inhibitors in addition to insulin therapy for treating type 2 diabetes mellitus (T2DM), a meta-analysis was performed to evaluate the efficacy and safety of this combination for T2DM by searching available randomized trials from PubMed, Embase, CENTRAL and ClinicalTrials.gov. Our meta-analysis included seven eligible placebo-controlled trials involving 4235 patients. Compared with placebo, SGLT2 inhibitor treatment was significantly associated with a mean reduction in HbA1c of −0.56%, fasting plasma glucose of −0.95 mmol/L, body weight of −2.63 kg and insulin dose of −8.79 IU, but an increased risk of drug-related adverse events by 36%, urinary tract infections by 29% and genital infections by 357%. No significant increase was observed in risk of overall adverse events [risk ratio (RR), 1.00], serious adverse events (RR, 0.90), adverse events leading to discontinuation (RR, 1.16), hypoglycaemia events (RR, 1.07) and severe hypoglycaemia events (RR, 1.24). No diabetic ketoacidosis events were reported. Further studies are needed to establish optimal combination type and dose.

AB - Given inconsistent trial results of sodium-glucose cotransporter 2 (SGLT2) inhibitors in addition to insulin therapy for treating type 2 diabetes mellitus (T2DM), a meta-analysis was performed to evaluate the efficacy and safety of this combination for T2DM by searching available randomized trials from PubMed, Embase, CENTRAL and ClinicalTrials.gov. Our meta-analysis included seven eligible placebo-controlled trials involving 4235 patients. Compared with placebo, SGLT2 inhibitor treatment was significantly associated with a mean reduction in HbA1c of −0.56%, fasting plasma glucose of −0.95 mmol/L, body weight of −2.63 kg and insulin dose of −8.79 IU, but an increased risk of drug-related adverse events by 36%, urinary tract infections by 29% and genital infections by 357%. No significant increase was observed in risk of overall adverse events [risk ratio (RR), 1.00], serious adverse events (RR, 0.90), adverse events leading to discontinuation (RR, 1.16), hypoglycaemia events (RR, 1.07) and severe hypoglycaemia events (RR, 1.24). No diabetic ketoacidosis events were reported. Further studies are needed to establish optimal combination type and dose.

KW - insulin therapy

KW - meta-analysis

KW - SGLT2 inhibitor

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85006893267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006893267&partnerID=8YFLogxK

U2 - 10.1111/dom.12785

DO - 10.1111/dom.12785

M3 - Article

C2 - 27598833

AN - SCOPUS:85006893267

VL - 19

SP - 142

EP - 147

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 1

ER -